Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer

[1] Berenson JR(2006)Treatment strategies for skeletal complications of cancer Cancer Biol Ther 5 1074-1077

[2] Rajdev L(2011)Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 813-822

[3] Broder M(2003)Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 61 1115-1117

[4] Fizazi K(2017)Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacial Surgeons J Bone Miner Metab 35 6-19

[5] Carducci M(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update J Oral Maxillofac Surg 72 1938-1956

[6] Smith M(2019)Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline J Clin Oncol 37 2270-2290

[7] Damião R(2015)Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43 847-854

[8] Brown J(2018)Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor? PLoS ONE 13 e0201343-25

[9] Karsh L(2002)Radiological aspects of apical periodontitis Endodontic Topics 1 3-12

[10] Milecki P(1993)Cracked and broken teeth–definitions, differential diagnosis and treatment Refuat Hapeh Vehashinayim 24 7-100

[1] Berenson JR(2006)Treatment strategies for skeletal complications of cancer Cancer Biol Ther 5 1074-1077

[2] Rajdev L(2011)Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 813-822

[3] Broder M(2003)Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 61 1115-1117

[4] Fizazi K(2017)Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacial Surgeons J Bone Miner Metab 35 6-19

[5] Carducci M(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update J Oral Maxillofac Surg 72 1938-1956

[6] Smith M(2019)Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline J Clin Oncol 37 2270-2290

[7] Damião R(2015)Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43 847-854

[8] Brown J(2018)Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor? PLoS ONE 13 e0201343-25

[9] Karsh L(2002)Radiological aspects of apical periodontitis Endodontic Topics 1 3-12

[10] Milecki P(1993)Cracked and broken teeth–definitions, differential diagnosis and treatment Refuat Hapeh Vehashinayim 24 7-100